BULLISHWHALES
BullishWhales · Congress · Trade Detail
--Innate Immunotherapeutics Stock, Australian Stock Exchange Symbol
RepublicanHouse

Chris Collins bought Innate Immunotherapeutics Stock, Australian Stock Exchange Symbol (--)

Chris Collins (R-NY), a U.S. Representative, has disclosed 40 trades in Innate Immunotherapeutics Stock, Australian Stock Exchange Symbol (--) since 2012, 16 purchases and 24 sales, worth an estimated $19M in disclosed volume (the midpoint of the dollar ranges members report, not exact amounts).

The trade highlighted here is a purchase: Chris Collins bought $500,001 - $1,000,000 of Innate Immunotherapeutics Stock, Australian Stock Exchange Symbol (--) on February 5, 2016. Since that trade, -- is up +0.00% against the S&P 500 up +372.93%, an outperformance of -372.93%.

Across these filings, Chris Collins has been a net seller of -- (a buy-to-sell ratio of 0.67). The most recent disclosed -- transaction shown was dated June 25, 2018. Each row in the table below links to that trade and its post-trade performance versus the market.

Data updated

-- trades
40
Disclosed Vol
$19M
Buys
16
40%
Sells
24
60%
Buy / Sell
0.67
ratio
First → Last
2012–2018

Chris Collins's -- trades vs the price

-- is up +0.00% since Chris Collins bought on February 5, 2016, versus +372.93% for the S&P 500.

Performance since this trade

Price change since trade
+0.00%
S&P 500 change since trade
+372.93%
Outperformance vs S&P 500
-372.93%

All Chris Collins -- trades

TradedTypeSizeReturnEst. profit
June 25, 2018SELL$250,001 - $500,000N/A
February 20, 2018SELL$15,001 - $50,000N/A
August 18, 2017BUY$250,001 - $500,000N/A
February 24, 2017SELL$15,001 - $50,000N/A
October 26, 2016BUY$100,001 - $250,000N/A
February 5, 2016BUY$500,001 - $1,000,000N/A
November 2, 2015BUY$1,000,001 - $5,000,000N/A
July 31, 2015BUY$250,001 - $500,000N/A
July 24, 2015SELL$15,001 - $50,000N/A
June 10, 2015BUY$15,001 - $50,000N/A

Estimated profit is shown for buys only, marked to the latest close. It is an estimate and does not net later sells, taxes, or fees.

Chris Collins & -- trading FAQ

Is it legal for Chris Collins to trade Innate Immunotherapeutics Stock, Australian Stock Exchange Symbol (--) stock?

Yes. Members of Congress are allowed to trade individual stocks, including Innate Immunotherapeutics Stock, Australian Stock Exchange Symbol (--), but the STOCK Act of 2012 requires them to publicly disclose each transaction within 45 days. BullishWhales tracks those disclosures; this page does not imply the trade was improper.

When did Chris Collins buy --?

Chris Collins disclosed a purchase of $500,001 - $1,000,000 of Innate Immunotherapeutics Stock, Australian Stock Exchange Symbol (--) on February 5, 2016, according to public STOCK Act filings.

How has -- performed since Chris Collins's trade?

Since Chris Collins bought -- on February 5, 2016, the stock is up +0.00%, versus +372.93% for the S&P 500 over the same period, an outperformance of -372.93%.

How many times has Chris Collins traded --?

Chris Collins has disclosed 40 -- trades since 2012 (16 purchases and 24 sales). Every disclosed trade is listed on this page.

How soon must members of Congress disclose a trade?

Under the STOCK Act, members of Congress must publicly report a covered transaction within 45 days of the trade. Filings can still be delayed, amended, or contain errors.

Where can I see all congressional -- trades?

BullishWhales tracks every disclosed congressional trade in Innate Immunotherapeutics Stock, Australian Stock Exchange Symbol (--) on the Innate Immunotherapeutics Stock, Australian Stock Exchange Symbol congressional trading page, which aggregates filings across all members of Congress.

Chris Collins's -- tradesAll congressional filings for Innate Immunotherapeutics Stock, Australian Stock Exchange SymbolChris Collins's full profile

Not investment advice. Congressional trading data is sourced from public STOCK Act disclosures, which are filed with a delay and may contain errors or be revised. Estimated prices and post-trade returns are derived algorithmically from public filings and end-of-day market data and describe historical activity, not a recommendation. Always do your own research and consult a licensed financial advisor before making investment decisions.

v1.0.30